, Volume 225, Issue 3, pp 637–646

Self-administration of gamma-hydroxybutyric acid (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons

  • Amy K. Goodwin
  • Barbara J. Kaminski
  • Elise M. Weerts
Original Investigation



Gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) are gamma-hydroxybutyrate (GHB) pro-drugs and drugs of abuse.


Given the reports of abuse, and the ease at which GBL and 1,4-BD may be obtained, we investigated the reinforcing effects of GBL (n = 5) and 1,4-BD (n = 4) in baboons using IV self-administration procedures.


Sessions ran 24 h/day. Each injection was contingent upon completion of a fixed number (120 or 160) of lever responses. A 3-h timeout period followed each injection, limiting the total number of injections to eight per day. Self-administration was first established with cocaine (0.32 mg/kg/injection). GBL (10–130.0 mg/kg/injection), 1,4-BD (10–100 mg/kg/injection), or vehicle was substituted for cocaine for at least 15 days. Food pellets were available ad libitum 24 h/day and were contingent upon completion of ten lever responses.


GBL (32–100 mg/kg/injection) maintained significantly greater numbers of injections when compared to vehicle in four of five baboons, and the mean rates of injection were high (more than six per day) in three baboons and moderate in the fourth baboon (four to six per day). 1,4-BD (78–130 mg/kg/injection) maintained significantly greater numbers of injections when compared to vehicle in only two out of four baboons, and mean rates were moderate to high in both baboons. Self-injection of these doses of GBL and 1,4-BD generally inhibited food-maintained responding.


GBL and 1,4-BD have abuse liability. Given that GBL and 1,4-BD are self-administered, are easier to obtain than GHB, and are detected in seized samples, additional legal control measures of these GHB pro-drugs may be needed.


Gamma-hydroxybutyrate Self-administration Abuse liability Zolpidem Cocaine Reinforcement Operant behavior Drug abuse 


  1. Andresen H, Aydin BE, Mueller A, Iwersen-Bergmann S (2011) An overview of gamma-hydroxybutyric acid: pharmacodynamics, pharmacokinetics, toxic effects, addiction, analytical methods, and interpretation of results. Drug Test Anal 3:560–8Google Scholar
  2. Arena C, Fung HL (1980) Absorption of sodium gamma-hydroxybutyrate and its prodrug gamma- butyrolactone: relationship between in vitro transport and in vivo absorption. J Pharm Sci 69:356–358PubMedCrossRefGoogle Scholar
  3. Ator NA (2000) Zaleplon and triazolam: drug discrimination, plasma levels and self-administration in baboons. Drug Alcohol Depend 61:55–68PubMedCrossRefGoogle Scholar
  4. Ator NA (2002) Relation between discriminative and reinforcing effects of midazolam, pentobarbital, chlordiazepoxide, zolpidem, and imidazenil in baboons. Psychopharmacology (Berl) 163:477–487CrossRefGoogle Scholar
  5. Beardsley P, Balster R, Harris L (1996) Evaluation of the discriminative stimulus and reinforcing effects of gammahydroxybutyrate (GHB). Psychopharmacology (Berl) 127:315–322Google Scholar
  6. Bell J, Collins R (2011) Gamma-butyrolactone (GBL) dependence and withdrawal. Addiction 106:442–447PubMedCrossRefGoogle Scholar
  7. Carter LP, Pardi D, Gorsline J, Griffiths RR (2009) Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. Drug Alcohol Depend 104:1–10PubMedCrossRefGoogle Scholar
  8. CDC (1999) Adverse events associated with ingestion of gamma-butyrolactone: Minnesota, New Mexico, and Texas, 1998–1999. U.S. Government Printing Office, Atlanta, pp 137–140Google Scholar
  9. Couper FJ, Thatcher JE, Logan BK (2004) Suspected GHB overdoses in the emergency department. J Anal Toxicol 28:481–484PubMedGoogle Scholar
  10. DEA (2000) Placement of gamma-butyrolactone in List I of the Controlled Substances Act (21 U.S.C. 802(34)). Drug Enforcement Administration, Justice. Final rule. Fed Regist 65:21645–21647Google Scholar
  11. Duer WC, Byers KL, Martin JV (2001) Application of a convenient extraction procedure to analyze gamma-hydroxybutyric acid in fatalities involving gamma-hydroxybutyric acid, gamma-butyrolactone, and 1,4-butanediol. J Anal Toxicol 25:576–582PubMedGoogle Scholar
  12. ECDD WHO (2012) Gamma-hydroxybutyric acide (GHB) critical review report. In: World Health Organization (WHO), 35th Expert Committee on Drug Dependence (ECDD): Hammamet, TunisiaGoogle Scholar
  13. EMCDDA (2008) GHB and its precursor GBL: an emerging trend case study. European Monitoring Centre for Drugs and Drug Addiction thematic paper. EMCDDA, LisbonGoogle Scholar
  14. Galloway GP, Frederick SL, Staggers FE, Gonzales M, Stalcup SA, Smith DE (1997) Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 92:89–96PubMedCrossRefGoogle Scholar
  15. Galloway GP, Frederick-Osborne SL, Seymour R, Contini SE, Smith DE (2000) Abuse and therapeutic potential of gamma-hydroxybutyric acid. Alcohol 20:263–269PubMedCrossRefGoogle Scholar
  16. Goodwin AK, Froestl W, Weerts EM (2005) Involvement of gamma-hydroxybutyrate (GHB) and GABA-B receptors in the acute behavioral effects of GHB in baboons. Psychopharmacology (Berl) 180:342–351CrossRefGoogle Scholar
  17. Goodwin AK, Griffiths RR, Brown PR, Froestl W, Jakobs C, Gibson KM, Weerts EM (2006) Chronic intragastric admistration of gamma-butyrolactone (GBL) produces physical dependence in baboons. Psychopharmacology 189:71–82PubMedCrossRefGoogle Scholar
  18. Goodwin AK, Brown PR, Jansen EE, Jakobs C, Gibson KM, Weerts EM (2009) Behavioral effects and pharmacokinetics of gamma-hydroxybutyrate (GHB) precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) in baboons. Psychopharmacology (Berl) 204:465–476CrossRefGoogle Scholar
  19. Goodwin AK, Kaminski BJ, Griffiths RR, Ator NA, Weerts EM (2011) Intravenous self-administration of gamma-hydroxybutyrate (GHB) in baboons. Drug Alcohol Depend 114:217–224PubMedGoogle Scholar
  20. Griffiths RR, Weerts EM (1997) Benzodiazepine self-administration in humans and laboratory animals—implications for problems of long-term use and abuse. Psychopharmacology (Berl) 134:1–37CrossRefGoogle Scholar
  21. Griffiths R, Lukas S, Bradford L, Brady J, Snell J (1981) Self-injection of barbiturates and benzodiazepines in baboons. Psychopharmacology 75:101–109PubMedCrossRefGoogle Scholar
  22. Griffiths RR, Sannerud CA, Ator NA, Brady JV (1992) Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal. J Pharmacol Exp Ther 260:1199–1208PubMedGoogle Scholar
  23. Hillebrand J, Olszewski D, Sedefov R (2010) Legal highs on the Internet. Subst Use Misuse 45:330–340PubMedCrossRefGoogle Scholar
  24. Ingels M, Rangan C, Bellezzo J, Clark RF (2000) Coma and respiratory depression following the ingestion of GHB and its precursors: three cases. J Emerg Med 19:47–50PubMedCrossRefGoogle Scholar
  25. Irwin RD (1996) NTP Summary report on the mtabolism, disposition, and toxicity of 1,4-butanediol (CAS No 110-63-4). Natl Toxicol Prog Toxicity Rep Ser 54:1–28Google Scholar
  26. Jones AL (2010) Legal ‘highs’ available through the Internet-implications and solutions? QJM 103:535–536PubMedCrossRefGoogle Scholar
  27. Karila L, Reynaud M (2010) GHB and synthetic cathinones: clinical effects and potential consequences. Drug Test Anal 3:552–9Google Scholar
  28. Lukas SE, Griffiths RR, Bradford LD, Brady JV, Daley L (1982) A tethering system for intravenous and intragastric drug administration in the baboon. Pharmacol Biochem Behav 17:823–829PubMedCrossRefGoogle Scholar
  29. McDonough M, Kennedy N, Glasper A, Bearn J (2004) Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 75:3–9PubMedCrossRefGoogle Scholar
  30. McMahon LR, Coop A, France CP, Winger G, Woolverton WL (2003) Evaluation of the reinforcing and discriminative stimulus effects of 1,4-butanediol and gamma-butyrolactone in rhesus monkeys. Eur J Pharmacol 466:113–120PubMedCrossRefGoogle Scholar
  31. Miotto K, Darakjian J, Basch J, Murray S, Zogg J, Rawson R (2001) Gamma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict 10:232–241PubMedCrossRefGoogle Scholar
  32. Palmer R (2004) Gamma-butyrolactone and 1,4-butanediol: abused analogues of gamma-hydroxybutyrate. Toxicol Rev 23:21–31PubMedCrossRefGoogle Scholar
  33. Roth RH, Giarman NJ (1965) Preliminary report on the metabolism of g-butyrolactone and g-hydroxybutyric acid. Biochem Pharmacol 14:177–178PubMedCrossRefGoogle Scholar
  34. Rowlett JK, Lelas S (2007) Comparison of zolpidem and midazolam self-administration under progressive-ratio schedules: consumer demand and labor supply analyses. Exp Clin Psychopharmacol 15:328–337PubMedCrossRefGoogle Scholar
  35. Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Megarbane B (2012) The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila) 50:458–470CrossRefGoogle Scholar
  36. Schneir AB, Ly BT, Clark RF (2001) A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-butanediol. J Emerg Med 21:31–33PubMedCrossRefGoogle Scholar
  37. Shannon M, Quang LS (2000) Gamma-hydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol: a case report and review of the literature. Pediatr Emerg Care 16:435–440PubMedCrossRefGoogle Scholar
  38. Snead OC, Furner R, Liu CC (1989) In vivo conversion of gamma-aminobutyric acid and 1,4-butanediol to gamma-hydroxybutyric acid in rat brain. Studies using stable isotopes. Biochem Pharmacol 38:4375–4380PubMedCrossRefGoogle Scholar
  39. Stein LA, Lebeau R, Clair M, Martin R, Bryant M, Storti S, Monti P (2011) A web-based study of gamma hydroxybutyrate (GHB): patterns, experiences, and functions of use. Am J Addict 20:30–39PubMedCrossRefGoogle Scholar
  40. Teter CJ, Guthrie SK (2001) A comprehensive review of MDMA and GHB: two common club drugs. Pharmacotherapy 21:1486–1513PubMedCrossRefGoogle Scholar
  41. Vree TB, van Dalen R, Kleijn VD, Gimbrere JSF (1978) Pharmacokinetics of 1,4-butanediol and 4-hydroxybutyric acid in man, rhesus monkey, and dog. Anasthesiol Intensivmed Notfallmed Schmerzther 110:66–73Google Scholar
  42. Weerts EM, Griffiths RR (1998) Zolpidem self-injection with concurrent physical dependence under conditions of long-term continuous availability in baboons. Behav Pharmacol 9:285–297PubMedGoogle Scholar
  43. Weerts EM, Ator NA, Grech DM, Griffiths RR (1998) Zolpidem physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. J Pharmacol Exp Ther 285:41–53PubMedGoogle Scholar
  44. Weerts EM, Ator NA, Griffiths RR (1999) Comparison of the intravenous reinforcing effects of propofol and methohexital in baboons. Drug and Alcohol Depend 57:51–60CrossRefGoogle Scholar
  45. Weerts E, Goodwin A, Griffiths R, Brown P, Froestl W, Jakobs C, Gibson K (2005) Spontaneous and precipitated withdrawal after chronic intragastric administration of gamma-hydroxybutyrate (GHB) in baboons. Psychopharmacology (Berl) 179:678–687CrossRefGoogle Scholar
  46. Wojtowicz J, Yatema M, Wax P (2008) Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review. Can J Emerg Med 10:69–74Google Scholar
  47. Wood DM, Warren-Gash C, Ashraf T, Greene SL, Shather Z, Trivedy C, Clarke S, Rasmey J, Holt DW, Dargan PI (2008) Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gammabutyrolactone (GBL) and 1,4-butanediol (1,4-BD). Q J Med 101:23–29CrossRefGoogle Scholar
  48. Wood DM, Brailsford AD, Dargan PI (2011) Acute toxicity and withdrawal syndromes related to gamma-hydroxybutyrate (GHB) and its analogues gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD). Drug Test Anal 3:417–25Google Scholar
  49. Woolverton WL, Rowlett JK, Winger G, Woods JH, Gerak LR, France CP (1999) Evaluation of the reinforcing and discriminative stimulus effects of gamma-hydroxybutyrate in rhesus monkeys. Drug Alcohol Depend 54:137–143PubMedCrossRefGoogle Scholar
  50. Zvosec DL, Smith SW, McCutcheon JR, Spillane J, Hall BJ, Peacock EA (2001) Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med 344:87–94PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Amy K. Goodwin
    • 1
  • Barbara J. Kaminski
    • 1
  • Elise M. Weerts
    • 1
  1. 1.Department of Psychiatry and Behavioral Sciences, Behavioral Biology Research CenterJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations